CAPLIN POINT LABORATORIES LTD. - 524742 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
This is to inform that mentioned share certificate has been reported as lost by the shareholders of the Company.27-02-2023
27-02-2023
CAPLIN POINT LABORATORIES LTD. - 524742 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
This is to inform that below mentioned share certificates has been reported as lost by the shareholders of the Company24-02-2023
CAPLIN POINT LABORATORIES LTD. - 524742 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
This is to inform that mentioned share certificates has been reported as lost by the shareholders of the Company.17-02-2023
CAPLIN POINT LABORATORIES LTD. - 524742 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
Allotment of Equity Shares on Exercise of ESOPs17-02-2023
Caplin Steriles gets USFDA nod for Carboprost Tromethamine Injection USP
It is a generic therapeutic equivalent version of (RLD), HEMABATE injection, of Pfizer Inc and is used in treating severe bleeding post childbirth14-02-2023
CAPLIN POINT LABORATORIES LTD. - 524742 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Attaching herewith a Press Release regarding grant of USFDA approval for Carboprost Tromethamine Injection USP to our Subsidiary Caplin Steriles Limited. Request you to take the same on record.14-02-2023
CAPLIN POINT LABORATORIES LTD. - 524742 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Further to our letter dated February 11, 2023 on the outcome of the Board meeting, we enclose herewith the copy of newspaper advertisement with respect to financial results published in the Financial Express (English Newspaper) and Maalai Malar (Tamil Newspaper)13-02-2023
Q3FY23 Quarterly Result Announced for Caplin Point Laboratories Ltd.
Caplin Point Laboratories announced Q3FY23 results: Consolidated Q3FY23 & 9MFY23: Q3FY23 revenue at Rs 386 crore, up 15.0% YoY, as compared to Rs 336 crore in Q3FY22 PAT for the quarter is at Rs 97 crore, up 22.8% as compared to Rs 79 crore in Q3FY22 PAT increased by 21.1% to Rs 276 crore in 9MFY23, against Rs 228 crore in 9MFY22 Cash flow from operations at Rs 176 crore for 9MFY23 Basic EPS grew by 24% to Rs 36.17 in 9MFY23 against Rs 29.18 in 9MFY22 (not annualized) With the depreciation of INR against USD, exchange gain in 9MFY23 is Rs 13.16 crore vs Rs 8.24 crore in 9MFY22 Enhanced deployment of cash has yielded an interest income of Rs 26 crore in 9MFY23 vs Rs.16 crore in 9MFY22 Considering the extended transit time and with a focus on the need to keep Inventory closer to customers, the current level of inventory is likely to continue in Q4 as well Geographical breakup of sales: LATAM & ROW: 86%, US: 14% Consolidated 9MFY23: Revenue for 9MFY23 grew by 17.2% YoY to Rs 1,122 crore Gross margins for 9MFY23 are at 54.8% EBITDA for 9MFY23 is Rs 362 crore; EBITDA margin at 32.2% 9MFY23 PAT is at Rs 276 crore, up 21.1% YoY Cash and cash equivalents at Rs 718 crore. Capex for 9MFY23 is at Rs 154 crore. Free cash flow for the period was Rs 22 crore Receivable stood stable around 100 days as of 9MFY23 Result PDF13-02-2023
CAPLIN POINT LABORATORIES LTD. - 524742 - Financial Results For The Quarter Ended December 31, 2022
Further to our intimation dated January 28, 2023 we wish to inform you that the Board of Directors of the Company at its meeting held today has, inter-alia approved the Un-audited standalone and consolidated financial results and the Limited Review Report (Annexure-1) of the Company as per Indian Accounting Standards for the quarter and nine months ended December 31, 2022. We also enclose a Press Release issued by the Company (Annexure 2) and an investor presentation in this regard (Annexure 3).11-02-2023
CAPLIN POINT LABORATORIES LTD. - 524742 - Board Meeting Outcome for Outcome Of The Board Meeting Held On February 11, 2023
Further to our intimation dated January 28, 2023 we wish to inform you that the Board of Directors of the Company at its meeting held today has, inter-alia approved the Un-audited standalone and consolidated financial results and the Limited Review Report (Annexure-1) of the Company as per Indian Accounting Standards for the quarter and nine months ended December 31, 2022. We also enclose a Press Release issued by the Company (Annexure 2) and an investor presentation in this regard (Annexure 3).11-02-2023